Ovarian Neoplasm Clinical Trial
Official title:
Support for Optimal Recovery Following Gynecologic Surgery Study (SOARING)
This trial studies how well two different supportive programs work in supporting optimal recovery in participants undergoing gynecological surgery. Supportive programs use different methods for helping participants cope with the surgical experience including gentle movements, counseling, writing, or relaxation techniques, and may help improve participants' well-being after gynecological surgery.
PRIMARY OBJECTIVES: I. To calculate recruitment, adherence, assessment completion, and retention rates. SECONDARY OBJECTIVES: I. Document the frequency of adverse events. II. Assess descriptive data on proposed outcomes (i.e., pain, sleep disturbances, psychological distress) for the next phase of study.) III. Qualitatively assess acceptability to guide future study planning. OUTLINE: Participants are randomized to 1 of 2 groups. GROUP I (MINDFUL MOVEMENT AND BREATHING [eMMB]): Participants will receive instruction on awareness meditation, breathing and relaxation, and awareness meditation. This will include a call with the interventionist to invite participants to initiate additional guidance upon request prior to surgery and a meeting by videoconferencing the day following surgery. Participants will also be given a self-directed video to be used before surgery and daily for two weeks following surgery. GROUP II (ATTENTION CONTROL [AC]): Participants will receive caring attention. This will include a call with the interventionist to invite participants to initiate additional guidance upon request prior to surgery and a meeting by videoconferencing the day following surgery. Participants are also asked to write brief diary entries once before surgery and daily for two weeks following surgery. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03667716 -
COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.
|
Phase 1 | |
Completed |
NCT01896778 -
Body Warming in Improving Blood Flow and Oxygen Delivery to Tumors in Patients With Cancer
|
N/A | |
Completed |
NCT03562897 -
Evaluation of Ocoxin-Viusid® in Advanced or Metastatic Ovarian Epithelial Cancer
|
Phase 2 | |
Completed |
NCT00248248 -
DOXIL for Consolidation Therapy in Ovarian Cancer.
|
Phase 2 | |
Recruiting |
NCT05960630 -
MIRRORS-RCT Pilot: Role of Robotic Interval Cytoreductive Surgery for Advanced Ovarian Cancer
|
N/A | |
Recruiting |
NCT05059782 -
Efficacy and Safety of Involving Field Radiotherapy in the Oligo-lesions(Metastasis/Recurrent/Refractory) of Ovarian Cancer
|
N/A | |
Recruiting |
NCT05752448 -
Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)
|
N/A | |
Completed |
NCT05751629 -
Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer
|
Phase 2 | |
Recruiting |
NCT04906187 -
Impact of Specific Monitoring of Intraoperative Analgesia Under General Anesthesia on Chronic Pain After Ovarian Cancer Surgery
|
N/A | |
Completed |
NCT01821833 -
Omega-3 Fatty Acid in Treating Pain in Patients With Breast or Ovarian Cancer Receiving Paclitaxel
|
N/A | |
Withdrawn |
NCT01477788 -
Prediction of Ovarian Malignancy in the Presence of Sonographic Pelvic Mass
|
N/A | |
Completed |
NCT05512676 -
Trabectedin/Caelyx vs Cisplatin Hypersensitivity in Relapsed Ovarian Cancer Patients Allergic to Platinum
|
||
Completed |
NCT04898842 -
Feasibility Study of a 4 Stage Bowel Obstruction Cancer Diet
|
N/A | |
Terminated |
NCT01374685 -
Family Communication of Hereditary Breast and Ovarian Cancer Risk Among African Americans
|
||
Completed |
NCT01139957 -
Incidence of Cancer in Women at Increased Genetic Risk of Ovarian Cancer
|
||
Active, not recruiting |
NCT05257408 -
Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer
|
Phase 3 | |
Completed |
NCT04573933 -
Survival Data and Characteristics of Finisterian Patients Treated With PARP Inhibitors for Ovarian Cancer Between 2014 and 2019.
|
||
Terminated |
NCT02470585 -
Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 3 | |
Completed |
NCT00001898 -
Microarray Analysis for Human Genetic Disease
|
N/A | |
Recruiting |
NCT04402333 -
Minimally Invasive Robotic Surgery, Role in Optimal Debulking Ovarian Cancer, Recovery & Survival
|